Pfizer wins HRT trial as new study knocks safety
Pfizer's Wyeth unit properly warned patients about the cancer risks of its Prempro drug, and so it isn't liable for one woman's breast cancer.
The latest lawsuit over hormone replacement therapy went Pfizer's way, but a new study has not. Yesterday, an Arkansas jury found that Pfizer's Wyeth unit properly warned patients about the cancer risks of its Prempro drug, and so it isn't liable for one woman's breast cancer. Cue the statements of disappointment from plaintiff's lawyers and contentment from Pfizer.
Pfizer's happiness didn't last long, however. About an hour later, research based on Women's Health Initiative data made its debut -- and it showed that not only do women who use estrogen-progestin therapy--like Prempro--for menopause experience an increased risk of cancer, but an increased severity of disease as well.
Some 385 women using the hormones developed invasive breast cancer over the 11-year study, compared with 293 women in the placebo group. More of the women on HRT had advanced breast cancer when diagnosed. The proportion of breast cancer-related death was increased as well. Until now, resear
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.